A Phase 1 clinical trial of SGR-3515 is ongoing to evaluate the safety and tolerability and to determine the maximum tolerated dose/recommended dose in patients with advanced solid tumors. Learn more at: CLINICALTRIALS.GOVPresentations Poster Presentation Discovery of potent, selective, and orally ...
These new data suggest that SGR-3515 is significantly more selective than existing compounds with low potential for drug-drug interaction. PRMT5-MTA Data at ENA 2024 Additionally, Schrödinger will present new preclinical data on its PRMT5-MTA inhibitor program at a poster session during the meet...